Breaking News | GenomeWeb

Breaking News

Exonics will use the funding to advance preclinical research from UT-Southwestern researcher Eric Olson on genome editing of DMD mutations in a mouse model.

The investment bank Evercore ISI upgraded Illumina's stock in anticipation of sales of its NovaSeq sequencing instrument.

Last week, GenomeWeb's readers were most interested in the US Supreme Court's ruling in favor of Life Technologies in Promega's 2010 patent infringement case.

The company will use the proceeds from the round to invest in sales and marketing efforts for its Sapientia clinical genome analysis platform, as well as for R&D.

The service will be incorporated into the Washington-based healthcare system's EHR system in order to advance its precision medicine efforts.

A retrospective analysis of Enterococcus faecium isolates from a UK hospital provided clues to infection sources and antibiotic resistance patterns.

The genome of the mite provides insight into the parasite's biology, which could identify gene-based strategies to control future infestations.

Mutation and predicted neoantigen profiles for more than 63,000 tumors suggests it would be difficult to design a broadly beneficial cancer vaccine.

The company sells the portable Hunter Real-Time PCR instrument for DNA analysis and a portfolio of test kits for use in food safety, food fraud, and microbiologically influenced corrosion.

The firm's topline performance for the full year was also higher than previous guidance provided by the company and analyst estimates.

The technologies monitor patient response to immunotherapies. 

Santen Inc., the US subsidiary of Japanese firm Santen Pharmaceuticals, will have exclusive rights to drug candidates discovered by twoXARs algorithms.

The researchers reported that New World H. pylori subpopulations reflected admixture of European and African strains, with some differences.

Using genotyping and tissue-specific expression data from the Genotype-Tissue Expression project, researchers characterized Neanderthal allele-specific expression.

The company sold shares, convertible debentures, and warrants to an institutional investor as part of a previously announced deal.

The deal comes about two years after OncoDNA made BioSequence the exclusive Spanish distributor of its clinical oncology molecular diagnostics.

Aviva will obtain assets including GenWay's CLIA facility, and its expertise in protein and assay production for research and clinical use.

The proceeds from the seed round will enable the company to fund the development and commercial launch of a $15 genomic test for dairy and beef cattle.

The combination test will allow clinicians to analyze breast cancer patients for germline hereditary cancer markers at the same time as they search their blood for driver mutations.

The company said the revenue increase was driven by strong growth in its ConfirmMDx prostate cancer test and the launch of its SelectMDx liquid biopsy test.

The firm reported $3.5 million in revenue for the three months ended Dec. 31, 2016, and $12.9 million for the full year.

In a conference call to discuss the firm's fourth-quarter and full-year earnings, senior management highlighted recent developments and outlined expectations for 2017.

Pages

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.